

Curriculum vitae - Ivo Graziadei

Persönliche Daten:

Geburtsdatum: 15.3.1964

Geburtsort: Innsbruck

Familienstand: verheiratet, 2 erwachsene Kinder

Dzt. Position:

Vorstand der Abteilung Innere Medizin, Landeskrankenhaus Hall i.T. (seit März 2013)

Ao. Univ. Prof. der Medizinischen Universität Innsbruck (seit März 1999)

Ausbildung:

Akademisches Gymnasium Innsbruck - **Matura Juni 1982**

Medizinstudium an der Universität Innsbruck: Oktober 1982 - Juni 1988

Auslandsfamulaturen während des Studiums:

University of Iowa, Iowa City, USA, Dept. of Pediatric Cardiology and Dept. of
Neurology

I. Medizinischen Univ. Klinik des Großkrankums Großhadern, München

Promotion: 2. Juli 1988

amerikanisches Staatsexamen - ECFMG (Education Commission of Foreign Medical
Graduates) bestanden Jänner 1992

Medizinische Tätigkeit / Ausbildungen:

Wissenschaftliche Tätigkeit:

15. Juli 1988 - 15. September 1989:

Gastarzt am Institut für Biochemische Pharmakologie der Universität Innsbruck

Turnusarztstätigkeit:

1. Oktober 1989 - 31. August 1990:

AÖ Krankenhaus der Barmherzigen Schwestern in Linz (Innere Medizin, Chirurgie)

1. September 1990 - 31. März 1991:

Universitätsklinik Innsbruck (Chirurgie, Unfallchirurgie, Innere Medizin)

Facharztausbildung Innere Medizin:

1. April 1991- 30. September 1996:

Univ. Assistent an der Univ. Klinik für Innere Medizin Innsbruck

1. Oktober 1995 - 31. März 1996:

Clinical Fellowship bei Prof. Dr. Roger Williams am Institute of Liver Studies, King's College School of Medicine and Dentistry in London, UK.

Facharzt für Innere Medizin: 1. April 1996

Clinical Fellowship (Hepatology):

29. Juni 1996 - 27. Juni 1997:

Clinical Fellowship am Dept. of Gastroenterology & Hepatology der Mayo Clinic, Mayo Foundation, Rochester, Minnesota, USA.

Ärztliche Tätigkeit:

1. Juli 1997 – 28.2.2013:

Oberarzt an der Univ. Klinik für Innere Medizin II (Schwerpunkt Gastroenterologie & Hepatologie) der Medizinischen Universität Innsbruck

seit 1.12.2001: **Additivfacharzt für Gastroenterologie & Hepatologie**

seit 31.5.2003: **Additivfacharzt für Internistische Intensivmedizin**

1.11.2002 – 28.2.2013:

Leitender OA der Gastroenterologischen Ambulanz

1.4.2004 – 28.02.2013:

Stellvertretender Direktor der Univ. Klinik für Innere Medizin II in Innsbruck

Seit 1.3.2013:

Vorstand der Abteilung für Innere Medizin, Landeskrankenhaus Hall i.T.,

Akademisches Lehrkrankenhaus der Medizinischen Universität Innsbruck

Lehre und Forschung:

26. November 1998: Habilitation mit Lehrbefugnis für das Fach Innere Medizin

Seit März 1999: Ao. Univ. Prof. der Medizinischen Universität Innsbruck

Publikationen:

> 140 Original Beiträge in peer-reviewed Journalen, zahlreiche Buchartikel

Wissenschaftspreise:

- Forschungspreis der Firma HOECHST 1993
- Paracelsus-Preis 1994 (Preis der Österreichischen Gesellschaft für Innere Medizin)
- Preis der Ärztekammer für Tirol und Vorarlberg 1994

Editorialboard:

Associate Editor "Liver Transplantation"

Mitglied des Editorialboards von "Hepatology", "Journal of Hepatology" und "Transplant International"

Reviewtätigkeit für zahlreiche weitere international Journale

Vortragstätigkeiten und Kongressorganisationen:

- Organisation (Kongresspräsident, -sekretär) zahlreicher (inter)nationaler Kongresse und ärztlicher Fortbildungen auf dem Gebiet der Inneren Medizin
- Laufende Vortragstätigkeiten an (inter)nationalen Kongressen und bei (über)regionalen Fortbildungsveranstaltungen

Studien:

Principal- und Subinvestigator zahlreicher (inter)nationaler Phase 2-4 Studien zu diversen Gebieten der Inneren Medizin, insbesondere Gastroenterologie & Hepatologie und hepatobiliäre Onkologie.

Lehrtätigkeit:

- Praktikum aus Innere Medizin, Universität Innsbruck (Sommersemester 1991 bis Sommersemester 1995, ab Wintersemester 1997/98)
- Betreuung von Dissertationen (n=18) und Diplomarbeiten (n=12) (SS 1999 - heute)
- Seminar: ausgewählte Kapitel aus Lebertransplantation
- Hauptvorlesung Innere Medizin
- Betreuung von KPJ Studenten an der Med. Univ. Innsbruck
- Unterricht am Ausbildungszentrum West der TILAK in Innsbruck (Gastroenterologie & Hepatologie) für Intensivpflegepersonal
- Tutortätigkeit bei Endoskopischen Fortbildungen und Ultraschall Seminaren
- Leiter der KPJ Ausbildung am LKH Hall (Akademische Lehrabteilung der Med. Univ. Innsbruck)

Mitgliedschaften:

- Österreichische Gesellschaft für Innere Medizin (ÖGIM) (Sekretär und Kassier der Sektion Tirol & Vorarlberg der Österr. Gesellschaft für Innere Medizin 2004-2011)
- Österreichische Gesellschaft für Transplantation, Transfusion und Genetik (ATX) (Vorstandsmitglied 2001-2016)
- Vorstandsmitglied der Österreichische Gesellschaft für Gastroenterologie und Hepatologie (Leiter der AG Onkologie 2004 – 2010 und AG Hepatologie 2010-2014, Bereit für Lebertransplantation seit 2014)
- American Association for the Study of Liver Diseases (AASLD)
- European Association for the Study of the Liver (EASL)
- International Liver Transplant Society (ILTS)
- European Society of Solid Organ Transplantation (ESOT)

Publications:

I. original articles

1. G.Zernig, T.Moshammer, **I.Graziadei**, and H.Glossmann (1988) The mitochondrial high-capacity low-affinity ($\pm$)-[3H]-nitrendipine binding site is regulated by nucleotides. Eur J Pharmacol 157, 67-73.
2. **I.Graziadei**, G.Zernig, R.Boer, and H.Glossmann (1989) Stereoselective binding of niguldipine enantiomers to α 1a-adrenoceptors labeled with [3H]-5-Methylurapidil. Eur J Pharmacol 172, 329 - 337.
3. **I.Graziadei**, G.Zernig, A.Grassegger, R.Boer, C.Schudt and H.Glossmann (1989) Hydrophobic calcium channel ligands: methodical problems and their solution. Am J Cardiol 64, 43I - 50I.
4. B.I.Armah, D.Muster, A.Raap, R.Brückner, and **I.Graziadei** (1989) Lack of stereoselectivity in the inotropic and phosphodiesterase inhibitory effects of saterinone enantiomers. Arzneim.-Forsch./Drug Res. 39 (II), 11, 1384 - 1392.
5. K.Stoschitzky, W.Klein, G.Stark, U.Stark, G.Zernig, **I.Graziadei**, and W.Lindner (1990) Different stereoselective effects of (R)- and (S)-propafenone: Clinical pharmacologic, electrophysiologic and radioligand binding studies. Clin Pharmacol Ther 47, 740 - 746.

6. G.Zernig, **I.Graziadei**, T.Moshammer, C.Zech, N.Reider, and H.Glossmann (1990) Mitochondrial Ca²⁺-antagonist binding sites are associated with an inner mitochondrial membrane anion channel. *Mol Pharmacol* 38, 362 - 369.
7. **I.Graziadei**, R.Kaserbacher, H.Braunsteiner, and W.Vogel (1993) The hepatic acute phase proteins alpha-1-antitrypsin and alpha-2-macroglobulin inhibit binding of transferrin to its receptor. *Biochem J* 290, 109-114.
8. **I.Graziadei**, S.Gaggl, R.Kaserbacher, H.Braunsteiner, and W.Vogel (1994) The acute phase protein alpha-1-antitrypsin inhibits growth and proliferation of human early erythroid progenitor cells (BFU-E) and of human erythroleukemic cells (K562) in vitro by interfering with transferrin iron uptake. *Blood* 83, 260-268.
9. G.Weiss, **I.Graziadei**, M.Urbaneck, K.Grünwald, and W.Vogel (1996) Divergent effects of alpha1-antitrypsin on the regulation of iron metabolism in human erythroleukaemic (K562) and myelomonocytic (THP-1) cells. *Biochem J* 319, 897-902.
10. W.Vogel, **I. Graziadei**, F. Umlauf, C. Datz, F. Hackl, S. Allinger, K. Grünwald, J. Patsch (1996). High-dose interferon- α 2b treatment prevents chronicity in acute hepatitis C: a pilot study. *Dig Dis Sci* 12, 81S-85S.
11. **I.Graziadei**, G.Weiss, A.Böhm, G.Werner-Felmayer, and W.Vogel (1997) Unidirectional upregulation of the synthesis of the major iron proteins, transferrin-receptor and ferritin, in HepG2 cells by the acute-phase protein 1-antitrypsin. *J Hepatol* 27, 716 - 725.
12. C.Datz, MRA Lalloz, W.Vogel, **I.Graziadei**, F.Hackl, G.Vautier, DM Layton, T.Maier-Dobersberger, P.Ferenci, E.Penner, F.Sandhofer, A.Bomford, and B.Paulweber (1997). Predominance of the HLA-H Cys282Tyr mutation in Austrian patients with genetic haemochromatosis. *J Hepatol* 27, 773 - 779.
13. **IW Graziadei**, RH Wiesner, PJ Marotta, MK Porayko, LJ Dahlke, SM Wilson, JL Steers, RAF Krom (1997). Neoral compared to Sandimmune is associated with a decrease in Histologic severity of rejection in patients undergoing primary liver transplantation. *Transplantation* 64, 726 - 731.
14. **I.Graziadei**, CM Kähler, CJ Wiedermann, and W.Vogel (1998). The acute-phase protein alpha-1-antitrypsin inhibits transferrin-receptor binding and proliferation of human skin fibroblasts. *Biochim Biophys Acta* 1401, 170-176.

15. **I.Graziadei**, T.Kelly, M.Schirmer, F.Geisen, W.Vogel, and G.Konwalinka (1998) Antitumor activity of the nucleoside analogs 2-Chlorodeoxyadenosine and 2',2'-Difluorodeoxycytidine on human hepatoma HepG2 cells. *J Hepatol* 28, 504-509.
16. EV Loftus, HA Aguilar, WJ Sandborn, WJ Tremaine, RAF Krom, AR Zinsmeister, **IW Graziadei**, and RH Wiesner (1998) Risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis following orthotopic liver transplantation. *Hepatology* 27, 685-690.
17. **I. Graziadei**, G.Weiss, C.Egger, D.Niederwieser, JR Patsch, and W.Vogel (1998) Modulation of iron metabolism in monocytic THP-1 cells and cultured human monocytes by the acute phase protein 1-antitrypsin. *Exp Hematol* 26, 1053-1060.
18. A. Propst, **I.Graziadei**, T.Propst, M.Herold, and W.Vogel (1998) The acute phase protein alpha-1-antitrypsin inhibits transferrin uptake in PLC/PRF/5 cells and increases release of hepatitis-B-virus surface-antigen and alpha-fetoprotein. *Eur J Gastroenterol Hepatol* 10, 497-502.
19. **IW Graziadei**, JJ Joseph, RH Wiesner, TM Therneau, KP Batts, and MK Porayko (1998) Increased risk of chronic liver failure in adults with heterozygous alpha 1-antitrypsin deficiency. *Hepatology* 28, 1058-1063.
20. **IW Graziadei**, RH Wiesner, KP Batts, PJ Marotta, NF LaRusso, MK Porayko, JE Hay, GJ Gores, J Ludwig, JJ Poterucha, JL Steers, and RAF Krom (1999) Recurrence of Primary Sclerosing Cholangitis following liver transplantation. *Hepatology* 29, 1050-1056.
21. **IW Graziadei**, RH Wiesner, PJ Marotta, MK Porayko, JE Hay, MK Charlton, JJ Poterucha, CB Rosen, GJ Gores, NF LaRusso and RAF Krom (1999) Long-term results of patients undergoing liver transplantation for primary sclerosing cholangitis. *Hepatology* 30, 1121-1127.
22. Spechtenhauser B, Hochleitner BW, Konigsrainer A, Mair P, Hormann C, Steurer W, Vogel W, **Graziadei I**, Margreiter R (1999) Combined liver-kidney transplantation: a single-center report. *Transplant Proc* 31; 3177-80.
23. **I.Graziadei**, W. Vogel and A.Bomford (2000) A novel binding site for the native hepatic acute-phase protein a1-antitrypsin expressed on the human hepatoma cell line Hep G2 and intestinal cell line Caco 2. *Liver* 20; 240-46.

24. R. Margreiter, A.Königsrainer, B.Spechtenhauser, R.Ladurner, A.Pomarolli, Ch. Hörmann, W.Steurer, **I.Graziadei** and W. Vogel (2002) Our experience with combined liver-kidney transplantation: an update. Transplant Proc 34; 2491-92.
25. H. Tilg, R. Jalan, A. Kaser, NA Davies, FA Offner, SJ Hodges, O. Ludwiczek, D. Shawcross, H. Zoller, A. Alisa, RP Mookerjee, **I. Graziadei**, C. Datz, M. Trauner, D. Schuppan, P. Obrist, W. Vogel and R. Williams (2003). Anti-tumor necrosis factor-alpha monoclonal antibody therapy in severe alcoholic hepatitis. J Hepatol 38; 419-425.
26. **IW Graziadei**, H. Sandmueller, P. Waldenberger, A. Koenigsrainer, K. Nachbaur, W. Jaschke, R. Margreiter and W. Vogel (2003) Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression on the waiting list and leads to excellent outcome. Liver Transplantation 9; 557-563.
27. S. Mechtcheriakov, **IW. Graziadei**, M. Mattedi, Th. Bodner, A. Kugener, HH. Hinterhuber, J. Marksteiner and W. Vogel (2004). Incomplete improvement of visuo-motor deficits in patients with minimal hepatic encephalopathy after liver transplantation. Liver Transplantation 10(1):77-83.
28. R. Bellmann, **IW. Graziadei**, C. Feistritzer, H. Schwaighofer, F. Stellaard, E. Sturm, CJ. Wiedermann and M. Joannidis (2004). Treatment of Refractory Cholestatic Pruritus after Liver Transplantation with Albumin Dialysis. Liver Transplantation 10(1): 107-114.
29. A. Kaser, O. Ludwiczek, S. Holzmann, AR Moschen, G. Weiss, E. Enrich, **I. Graziadei**, S. Dunzendorfer, CJ Wiedermann, E. Mürzl, E. Grasl, Z. Jasarevic, N. Romani, FA Offner and H. Tilg (2004). Increased expression of CCL 20 in human inflammatory bowel disease. J Clin Immunol 24: 74-85.
30. RO Koch, **IW Graziadei**, F. Schulz, K. Nachbaur, A. Königsrainer, R. Margreiter and W. Vogel (2004). Long-Term Efficacy and Safety of Mycophenolate Mofetil in Liver Transplant Recipients with Calcineurin Inhibitor-Induced Renal Dysfunction. Transplant International 17: 518-524.

31. R. Bellmann, C. Feistritzer, H. Zoller, **IW Graziadei**, H. Schwaighofer, CJ Wiedermann, M Joannidis (2004). Treatment of intractable pruritus in drug induced cholestasis with albumin dialysis: a report of two cases. *ASAIO J* 50: 387 – 391.
32. S. Mechtcheriakov, M Schocke, A Kugener, **IW Graziadei**, M Mattedi, H Hinterhuber, W Vogel and J Marksteiner (2005). Chemical shift magnetic resonance spectroscopy of cingulate grey matter in patients with minimal hepatic encephalopathy. *Neuroradiology* 47: 27-34.
33. S. Mechtcheriakov, **IW Graziadei**, M. Rettenbacher, I. Schuster, H. Hinterhuber, W. Vogel and J. Marksteiner (2005) Diagnostic value of fine motor deficits in patients with low-grade hepatic encephalopathy. *World J Gastroenterol* 11(18):2777-80
34. W. Mark, **I. Graziadei**, D. Bargehr, W. Vogel, C. Boesmueller, W. Tabarelli, A. Pomarolli, R. Ladumer, W. Steurer, A. Koenigsrainer, R. Margreiter and H. Bonatti (2005) Infectious complications limit the outcome of liver transplantation in medical urgency code 2 patients. *Transplant Proc.* 37(2):1224-6.
35. E. Boeckle, C. Boesmueller, S. Wiesmayr, W. Mark, M. Rieger, D. Tabarelli, **I. Graziadei**, D Hoefer, H. Antretter, I. Stelzmueller, J. Krugmann, R. Zangerle, H. Huemer, G. Poelzl, R. Margreiter and H. Bonatti (2005). Kaposi sarcoma in solid organ transplant recipients: a single center report. *Transplant Proc.* 37(4):1905-9.
36. G. Millonig, **IW Graziadei**, D. Eichler, K-H Pfeiffer, G. Finkenstedt, P. Muehllechner, A. Koenigsrainer, R. Margreiter and W Vogel (2005). Alendronate in combination with calcium and vitamin D prevents bone loss after liver transplantation: a prospective single center study. *Liver Transplantation* 11: 960-6.
37. S. Wiesmayr, I. Stelzmüller, W. Tabarelli, D. Bargehr, **I. Graziadei**, M. Freund, R. Ladurner, W. Steurer, C. Geltner, W. Mark, R. Margreiter and H. Bonatti (2005). Nocardiosis following solid organ transplantation: a single-centre experience. *Transpl. Int* 18:1048-53.
38. AR Moschen, A. Kaser, S. Stadlmann, G. Millonig, S. Kaser, P. Muehllechner, A. Habor, **I. Graziadei**, W. Vogel and H. Tilg (2005). The RANKL/OPG system and bone mineral density in patients with chronic liver disease. *J Hepatol* 43: 973-83.

39. S. Mechtcheriakov, **IW Graziadei**, A. Kugener, I. Schuster, J. Mueller, H. Hinterhuber, W. Vogel and J. Marksteiner (2005) Motor dysfunction in patients with liver cirrhosis: impairment of handwriting. *J Neurol* 1432-59.
40. S. Mechtcheriakov, **IW Graziadei**, A. Kugener, J. Wiedemann, C. Galbavy, H. Hinterhuber, J. Marksteiner and W. Vogel (2005). Multidimensional assessment of neuro-psychiatric symptoms in patients with low-grade hepatic encephalopathy: a clinical rating scale. *World J Gastroenterol* 11: 5893-8.
41. **IW Graziadei**, RO Koch, H. Schwaighofer, K. Nachbaur, A. Koenigsrainer, R. Margreiter and W. Vogel (2006) Long-term outcome of endoscopic treatment of biliary strictures after liver transplantation. *Liver Transplantation* 12: 718-25.
42. S. Mechtcheriakov, **IW Graziadei**, A. Kugener, I. Schuster, J. Mueller, H. Hinterhuber, W. Vogel and J. Marksteiner (2006). Motor dysfunction in patients with liver cirrhosis: impairment of handwriting. *J Neurol* 253: 349-56.
43. HL Tillmann, J. Hadem, L. Leifeld, K. Zachou, A. Canbay, C. Eisenbach, **I. Graziadei**, J. Encke, H. Schmidt, W. Vogel, A. Schneider, U. Spengler, G. Gerken, GN Dalekos, H. Wedemeyer and MP Manns (2006). Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience. *J Virol Hepat* 13: 256-63.
44. G. Millonig, T. Buratti, **IW Graziadei**, H. Schwaighofer, D. Orth, R. Margreiter and W. Vogel (2006). Bactobilia after liver transplantation: Frequency and antibiotic susceptibility. *Liver Transplantation* 12: 747-53.
45. MA Rettenbacher, S. Baumgartner, U. Eder-Ischia, M. Edlinger, **I. Graziadei**, A. Hofer, R. Huber, M. Hummer, G. Kemmler, E. Weiss, WW Fleischhacker (2006) Association between antipsychotic-induced elevation of liver enzymes and weight gain: a prospective study. *J Clin Psychopharmacol* 26: 500-503.
46. G. Millonig, **IW Graziadei**, MC Freund, W. Jaschke, S. Stadlmann, R. Ladurner, R. Margreiter and W. Vogel (2007) Response to preoperative chemoembolization correlates with outcome after liver transplantation in patients with hepatocellular carcinoma. *Liver Transplantation* 13: 272-279.

47. H. Zoller, M. Egg, **I. Graziadei**, M. Creus, AR Janecke, J. Löffler-Ragg and W. Vogel (2007). CFTR gene mutations in pancreatitis: frequency and clinical manifestations in an Austrian patient cohort. *Wien Klin Wochenschr* 119: 527-33.
48. I. Stelzmueller, C. Lass-Floerl, C. Geltner, **I. Graziadei**, S. Schneeberger, H. Antretter, L. Mueller, B. Zelger, N. Singh, TL Pruett, R. Margreiter and H. Bonatti (2008). Zygomycosis and other rare filamentous fungal infections in solid organ transplant recipients. *Transpl. Int.* 21: 534-546.
49. V. Mazzaferro, JM Llovet, R. Miceli, S. Bhoori, M. Schiavo, L. Mariani, T. Camerini, S. Roayaie, ME Schwartz, GL Grazi, R. Adam, P. Neuhaus, M. Salizzoni, J. Bruix, A. Forner, L. De Carlis, U. Cillo, AK Burroughs, R. Troisi, M. Rossi, GE Gerunda, J. Lerut, J. Belghiti, I. Boin, J. Gugenheim, F. Rochling, B. Van Hoek and P. Majno; Metroticket Investigator Study Group (**I. Graziadei**). (2009) Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. *Lancet Oncology* 10; 35-43.
50. M. Pinter, W. Sieghart, **I. Graziadei**, W. Vogel, A. Maieron, R. Königsberg, A. Weissmann, G. Kornek, C. Plank and M. Peck-Radosavljevic (2009). Sorafenib in Unresectable Hepatocellular Carcinoma from Mild to Advanced Stage Liver Cirrhosis. *The Oncologist* 14: 70-76.
51. M. Schranz, H. Talasz, **I. Graziadei**, T. Winder, C. Sergi, K. Bogner, W. Vogel and H. Zoller (2009) Diagnosis of hepatic iron overload: a family study illustrating pitfalls in diagnosing hemochromatosis. *Diagn Mol Pathol* 18:53-60.
52. A. Finkenstedt, **IW Graziadei**, K. Nachbaur, W. Jaschke, W. Mark, R. Margreiter and W. Vogel (2009) Transjugular intrahepatic portosystemic shunt in liver transplant recipients. *World J Gastroenterol* 15:1999-2004.
53. A. Finkenstedt, **IW Graziadei**, W. Oberaigner, W. Hilbe, K. Nachbaur, W. Mark, R. Margreiter and W. Vogel (2009) Extensive surveillance promotes early diagnosis and improved survival of de novo malignancies in liver transplant recipients. *Am J Transplant* 9: 2355-2361.
54. A. Moschen, C. Molnar, AM Wolf, H. Weiss, **I. Graziadei**, S. Kaser, CF Ebenbichler, S. Stadlmann, PL Moser and H. Tilg. (2009) Effects of weight loss induced by bariatric surgery on hepatic adipocytokine expression. *J Hepatol* 51: 765-777.

55. J. Lammer, K. Malagari, T. Vogl, F. Pilleul, A. Denys, A. Watkinson, M. Pitton, G. Sergeant, T. Pfammatter, S. Terraz, Y. Benhamou, Y. Avajon, T. Gruenberger, M. Pomoni, H. Langenberger, M. Schuchmann, J. Dumortier, C. Mueller, P. Chevallier, R. Lencioni; PRECISION V Investigators (I. **Graziadei**) (2010) Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. *Cardiovasc Intervent Radiol* 33: 41-52.
56. M. Peck-Radosavljevic, J. Deutsch, P. Ferenci, I. **Graziadei**, H. Hofer, H. Holzmann, WD Huber, H. Laferl, A. Maieron, R. Stauber, W. Vogel (2010). 4. Austrian consensus-statement for diagnosis and therapy of hepatitis B 2009 *Wien Klin Wochenschr.* 2010 May;122(9-10):280-302.
57. AR Moschen, C. Molnar, S. Geiger, I. **Graziadei**, CF Ebenbichler, H. Weiss, S. Kaser, A. Kaser, H. Tilg. (2010) Anti-inflammatory effects of excessive weight loss: potent suppression of adipose interleukin 6 and tumour necrosis factor expression. *Gut* 59(9):1259-64.
58. V. Rijckborst, MJ ter Borg, Y. Cakaloglu, P. Ferenci, F. Tabak, M. Akdogan, K. Simon, M. Raptopoulou-Gigi, N. Ormeci, PE Zondervan, E. Verhey, AJ van Vuuren, BE Hansen, HL Janssen, P. Munda, TM Scherzer, R. Staufer, W. Vogel, I. **Graziadei**, G. Gerken, C. Niederau, G. Germanidis, G. Hatzis, G. Kitis, P. Xiarchos, E. Gigi, E. Sinakos, I. Vafiadis-Zouboulis, P. Nicolaou, G. Paraskevi, P. Grima, G. Montalto, M. Russello, G. Scifo, A. Spadaro, S. Tripi, ML op den Brouw, SD Diepstraten, van GJ Doornum, C. van der Ent, A. Heijens, A. Keizerwaard, M. Ouwendijk, G. Ramdjan, LA van Santen, SM Scherbeijn, M. Schutten, W. Tielemans, AM Woltman, R. Woltman, TW Lapinski, W. Halota, T. Mach, M. Pazgan-Simon, US Akarca, G. Ersoz, N. Sasmaz, B. Pinarbasi, Z. Balik, H. Senturk. (2010) A randomized trial of peginterferon alpha-2a with or without ribavirin for HBeAg-negative chronic hepatitis B. *Am J Gastroenterol.* 105(8): 1762-9.
59. F. Krismer, JC Roos, M. Schranz, IW **Graziadei**, S. Mechtcheriakov, W. Vogel, RH Carpenter, H. Zoller. (2010) Saccadic latency in hepatic encephalopathy: a pilot study *Metab Brain Dis.* 25(3):285-95.
60. K. Eisendle, H. Müller, E. Ortner, H. Talasz, I. **Graziadei**, W. Vogel, R. Höpfl. (2010) Pruritus of unknown origin and elevated total serum bile acid levels in patients without clinically apparent liver disease. *J Gastroenterol Hepatol.* 26(4):716-21.

61. C. Ress, AR Moschen, N. Sausgruber, A. Tschoner, **I. Graziadei**, H. Weiss, W. Schgoer, CF Ebenbichler, RJ Konrad, JR Patsch, H. Tilg, S. Kaser. (2011) The role of apolipoprotein A5 in non-alcoholic fatty liver disease. *Gut* 60(7):985-91.
62. CM Kähler, **I. Graziadei**, H. Vogelsinger, S. Desole, K. Cima, W. Vogel. (2011) Successful treatment of portopulmonary hypertension with the selective endothelin receptor antagonist Sitaxentan. *Wien Klin Wochenschr.* 123(7-8):248-52.
63. D. Jodocy, S. Abbrederis, **IW Graziadei**, W. Vogel, O. Pachinger, GM Feuchtner, W. Jaschke, G. Friedrich. (2011). Coronary computer tomographic angiography for preoperative risk stratification in patients undergoing liver transplantation. *Eur J Radiol.* 2011 Jun 10 epub.
64. M. Pinter, W. Sieghart, F. Hucke, **I. Graziadei**, W. Vogel, A. Maieron, R. Königsberg, A. Weissmann, G. Kornek, J. Matejka, R. Stauber, R. Buder, B. Grünberger, M. Schöniger-Hekele, C. Müller, M. Peck-Radosavljevic M. (2011) Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib. *Aliment Pharmacol Ther.* 34(8):949-59.
65. M. Peck-Radosavljevic, W. Sieghart, C. Kölblinger, M. Reiter, M. Schindl, G. Ulbrich, R. Steininger, C. Müller, R. Stauber, M. Schöniger-Hekele, M. Gschwendtner, C. Plank, M. Funovics, **I. Graziadei**, J. Lammer, T. Gruenberger, G. Gastl, F. Karnel; Austrian Association of Gastroenterology, Hepatology (ÖGGH); Austrian Society of Interventional Radiology (ÖGIR); Austrian Society of Hematology and Oncology (ÖGHO); Austrian Society for Surgical Oncology (ASSO). (2012) Austrian Joint ÖGGH-ÖGIR-ÖGHO-ASSO position statement on the use of transarterial chemoembolization (TACE) in hepatocellular carcinoma. *Wien Klin Wochenschr.* 124(3-4):104-10.
66. **IW Graziadei**, HM Zoller, A. Schloegl, K. Nachbaur, KP Pfeiffer, W. Mark, G. Mikuz, J. Pratschke, R. Margreiter, W. Vogel. (2012) Early viral load and recipient interleukin-28B rs12979860 genotype are predictors of the progression of hepatitis C after liver transplantation. *Liver Transpl.* 18(6):671-9
67. A. Finkenstedt, L. Dorn, M. Edlinger, W. Prokop, L. Risch, A. Griesmacher, **I. Graziadei**, W. Vogel, H. Zoller. (2012) Cystatin C is a strong predictor of survival in patients with cirrhosis: is a cystatin C-based MELD better? *Liver Int.* 2012 Mar 1. doi: 10.1111/j.1478-3231.2012.02766.x. [Epub ahead of print]

68. LS Belli, R. Volpes, **I. Graziadei**, S. Fagiuoli, P. Starkel, P. Burra, AB Alberti, B. Gridelli, W. Vogel, L. Pasulo, E. De Martin, M. Guido, L. De Carlis, J. Lerut, U. Cillo, AK Burroughs, G. Pinzello. (2012) Antiviral therapy and fibrosis progression in patients with mild-moderate hepatitis C recurrence after liver transplantation. A randomized controlled study. *Dig Liver Dis.* 2012 Jul;44(7):603-9
69. M. Pinter, F. Huckle, **I. Graziadei**, W. Vogel, A. Maieron, R. Königsberg, R. Stauber, B. Grünberger, C. Müller, C. Kölblinger, M. Peck-Radosavljevic, W. Sieghart. (2012) Advanced-stage hepatocellular carcinoma: transarterial chemoembolization versus sorafenib. *Radiology.* 2012 May;263(2):590-9
70. W. Sieghart, M. Pinter, F. Huckle, **I. Graziadei**, M. Schöniger-Hekele, C. Müller, W. Vogel, M. Trauner, M. Peck-Radosavljevic M. (2013) A single determination of C-reactive protein at the time of diagnosis predicts long term outcome of patients with hepatocellular carcinoma. *Hepatology* 57(6):2224-34
71. W. Sieghart, F. Huckle, M. Pinter, **I. Graziadei**, W. Vogel, C. Müller, H. Heinzl, M. Trauner, M. Peck-Radosavljevic (2013) The ART of decision making: retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma. *Hepatology* 57(6):2261-73.
72. G. Orlando, R. Adam, D. Mirza, G. Soderdahl, RJ Porte, A. Paul, AK Burroughs, CA Seiler, M. Colledan, **I. Graziadei**, JC Garcia Valdecasas, FR Pruvot, V. Karam, J Lerut (2013) Hepatic hemangiosarcoma: an absolute contraindication to liver transplantation--the European Liver Transplant Registry experience. *Transplantation* 27;95(6):872-7.
73. M. Peck-Radosavljevic, B. Angermayr, C. Datz, A. Ferlitsch, M. Ferlitsch, V. Fuhrmann, M. Häfner, L. Kramer, A. Maieron, B. Payer, T. Reiberger, R. Stauber, R. Steininger, M. Trauner, S. Thurnher, G. Ulbrich, W. Vogel, H. Zoller, **I. Graziadei** (2013) Austrian Society of Gastroenterology and Hepatology. Austrian consensus on the definition and treatment of portal hypertension and its complications (Billroth II). *Wien Klin Wochenschr.* 125(7-8):200-19.
74. A. Finkenstedt, K. Nachbaur, H. Zoller, M. Joannidis, J. Pratschke, **IW Graziadei**, W. Vogel (2013) Acute-on-chronic liver failure: excellent outcomes after liver transplantation but high mortality on the wait list. *Liver Transpl.* 19(8):879-86.

75. K. Oettl, R. Birner-Gruenberger, W. Spindelboeck, HP Stueger, L. Dorn, V. Stadlbauer, C. Putz-Bankuti, P. Krisper, **I. Graziadei**, W. Vogel, C. Lackner, RE Stauber (2013) Oxidative albumin damage in chronic liver failure: relation to albumin binding capacity, liver dysfunction and survival. *J Hepatol.* 59(5):978-83.
76. A. Finkenstedt, C. Auer, B. Glodny, U. Posch, H. Steitzer, G. Lanzer, J. Pratschke, M. Biebl, M. Steurer, **I. Graziadei**, W. Vogel, H. Zoller (2013) Patatin-like phospholipase domain-containing protein 3 rs738409-G in recipients of liver transplants is a risk factor for graft steatosis. *Clin Gastroenterol Hepatol.* 11(12):1667-72
77. Q. Lai, AW Avolio, **I. Graziadei**, G. Otto, M. Rossi, G. Tisone, P. Goffette, W. Vogel, MB Pitton, J Lerut J; European Hepatocellular Cancer Liver Transplant Study Group (2013) Alpha-fetoprotein and modified response evaluation criteria in solid tumors progression after locoregional therapy as predictors of hepatocellular cancer recurrence and death after transplantation. *Liver Transpl.* 2013 Oct;19(10):1108-18.
78. F. Huckle, W. Sieghart, M. Pinter, **I. Graziadei**, W. Vogel, C. Müller, H. Heinzl, F. Waneck, M. Trauner, M. Peck-Radosavljevic (2014). The ART-strategy: sequential assessment of the ART score predicts outcome of patients with hepatocellular carcinoma re-treated with TACE. *J Hepatol.* 60(1):118-26.
79. S. Beinhardt, W. Leiss, AF Stättermayer, **I. Graziadei**, H. Zoller, R. Stauber, A. Maieron, C. Datz, P. Steindl-Munda, H. Hofer, W. Vogel, M. Trauner, P. Ferenci (2014) Long-term outcomes of patients with Wilson disease in a large Austrian cohort. *Clin Gastroenterol Hepatol.* 12(4):683-9.
80. W. Mark, R. Ollinger, H. Rumpold, D. Wolf, D. Nachbaur, F. Aigner, C. Margreiter, C. Gassner, H. Schennach, **I. Graziadei**, W. Vogel, R. Margreiter E. Gunsilius (2014) The liver graft as Trojan horse-multilineage donor-derived hematopoiesis after liver transplantation: case report. *Transplant Proc.* 2013 Nov;45(9):3438-41.
81. P. Malik, C. Kohl, B. Holzner, G. Kemmler, **I. Graziadei**, W. Vogel, B. Sperner-Unterweger (2014) Distress in primary caregivers and patients listed for liver transplantation. *Psychiatry Res.* 215(1):159-62.
82. C. Röss, PA Maeser, A. Tschoner, L. Loacker, K. Salzmann, G. Staudacher, A. Melmer, H. Zoller, W. Vogel, A. Griesmacher, H. Tilg, **I. Graziadei**, S. Kaser (2014) Serum prolactin in advanced chronic liver disease. *Horm Metab Res.* 46(11):800-3.

83. F. Huckle, M. Pinter, **I. Graziadei**, S. Bota, W. Vogel, C. Müller, H. Heinzl, F. Waneck, M. Trauner, M. Peck-Radosavljevic, W. Sieghart W (2014) How to STATE suitability and START transarterial chemoembolization in patients with intermediate stage hepatocellular carcinoma. *J Hepatol.* 2014 Dec;61(6):1287-96.
84. F. Kocher, A. Finkenstedt, M. Fiegl, **I. Graziadei**, G. Gamerith, W. Oberaigner, W. Vogel, W. Hilbe (2015) Liver Transplantation-Associated Lung Cancer: Comparison of Clinical Parameters and Outcomes. *Clin Lung Cancer.* Sep;16(5):e75-81
85. Finkenstedt A, Vikoler A, Portenkirchner M, Mülleder K, Maglione M, Margreiter C, Moser P, Vogel W, Bale R, Freund M, Luger A, Tilg H, Petersen J, Schneeberger S, **Graziadei I**, Zoller H, Glodny B. Excellent post-transplant survival in patients with intermediate stage hepatocellular carcinoma responding to neoadjuvant therapy. *Liver Int.* 2016 May;36(5):688-95.
86. Brandl A, Stolzlechner P, Eschertzhuber S, Aigner F, Weiss S, Vogel W, Krannich A, Neururer S, Pratschke J, **Graziadei I**, Öllinger R. Inferior graft survival of hepatitis B core positive grafts is not influenced by post-transplant hepatitis B infection in liver recipients--5-year single-center experience. *Transpl Int.* 2016 Apr;29(4):471-82
87. Pircher A, Jöhrer K, Kocher F, Steiner N, **Graziadei I**, Heidegger I, Pichler R, Leonhartsberger N, Kremser C, Kern J, Untergasser G, Gunsilius E, Hilbe W. Biomarkers of evasive resistance predict disease progression in cancer patients treated with antiangiogenic therapies. *Oncotarget.* 2016 Apr 12;7(15):20109-23.
88. Addolorato G, Bataller R, Burra P, DiMartini A, **Graziadei I**, Lucey MR, Mathurin P, O'Grady J, Pageaux G, Berenguer M. Liver Transplantation for Alcoholic Liver Disease. *Transplantation* 2016 May;100(5):981-7.
89. Nevens F, Andreone P, Mazzella G, Strasser SI, Bowlus C, Invernizzi P, Drenth JP, Pockros PJ, Regula J, Beuers U, Trauner M, Jones DE, Floreani A, Hohenester S, Luketic V, Shiffman M, van Erpecum KJ, Vargas V, Vincent C, Hirschfield GM, Shah H, Hansen B, Lindor KD, Marschall HU, Kowdley KV, Hooshmand-Rad R, Marmon T, Sheeron S, Pencek R, MacConell L, Pruzanski M, Shapiro D; POISE Study Group (**I. Graziadei**, et al.). A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis. *N Engl J Med.* 2016 Aug 18;375(7):631-43

90. **Graziadei I**, Zoller H, Fickert P, Schneeberger S, Finkenstedt A, Peck-Radosavljevic M, Müller H, Kohl C, Sperner-Unterwieser B, Eschertzhuber S, Hofer H, Öfner D, Tilg H, Vogel W, Trauner M, Berlakovich G. Indications for liver transplantation in adults : Recommendations of the Austrian Society for Gastroenterology and Hepatology (ÖGGH) in cooperation with the Austrian Society for Transplantation, Transfusion and Genetics (ATX). *Wien Klin Wochenschr.* 2016 Oct;128(19-20):679-690
91. Alcaraz-Quiles J, Titos E, Casulleras M, Pavesi M, López-Vicario C, Rius B, Lopategi A, de Gottardi A, **Graziadei I**, Gronbaek H, Ginès P, Bernardi M, Arroyo V, Clària J. Polymorphisms in the IL-1 gene cluster influence systemic inflammation in patients at risk for acute-on-chronic liver failure. *Hepatology.* 2017 Jan;65(1):202-216
92. Kozbial K, Aberle SW, Susser S, Al-Zoairy R, Moser S, Stättermayer AF, Maieron A, Gschwantler M, Stauber R, **Graziadei I**, Zoller H, Beinhardt S, Holzmann H, Munda-Steindl P, Hofer H, Sarrazin C, Ferenci P. Letter: retreatment of patients with chronic hepatitis C who have failed interferon-free combination therapy with direct acting anti-virals. *Aliment Pharmacol Ther.* 2017 Jan;45(2):373-375
93. Lai Q, Feys E, Karam V, Adam R, Klempnauer J, Oliverius M, Mazzaferro V, Pascher A, Remiszewski P, Isoniemi H, Pirenne J, Foss A, Ericzon BG, Markovic S, Lerut JP; European Liver Intestine Transplant Association (ELITA). Hepatic Epithelioid Hemangioendothelioma and Adult Liver Transplantation: Proposal for a Prognostic Score Based on the Analysis of the ELTR-ELITA Registry. *Transplantation.* 2017 Mar;101(3):555-564
94. Lai Q, Vitale A, Iesari S, Finkenstedt A, Mennini G, Spoletini G, Hoppe-Lotichius M, Vennarecci G, Manzia TM, Nicolini D, Avolio AW, Frigo AC, **Graziadei I**, Rossi M, Tsochatzis E, Otto G, Ettorre GM, Tisone G, Vivarelli M, Agnes S, Cillo U, Lerut J; European Hepatocellular Cancer Liver Transplant Study Group. Intention-to-treat survival benefit of liver transplantation in patients with hepatocellular cancer. *Hepatology.* 2017 Dec;66(6):1910-1919
95. Bilgicler C, Stadlmann A, Makristathis A, Thannesberger J, Kastner MT, Knoflach P, Steiner P, Schöniger-Hekele M, Högenauer C, Blesl A, Datz C, Huber-Schönauer U, Schöfl R, Wewalka F, Püspök A, Mitrovits N, Leiner J, Tilg H, Effenberger M, Moser M, Siebert F, Hinterberger I, Wurzer H, Stupnicki T, Watzinger N, Gombotz G, Hubmann R,

Klimpel S, Biowski-Frotz S, Schrutka-Kölbl C, **Graziadei I**, Ludwiczek O, Kundi M, Hirschl AM, Steininger C; Austrian Helicobacter Study Group of the Austrian Society of Gastroenterology and Hepatology. Prospective multicentre clinical study on inter- and inpatient genetic variability for antimicrobial resistance of *Helicobacter pylori*. Clin Microbiol Infect. 2018 Mar;24(3):267-272

96. Reiberger T, Püspök A, Schoder M, Baumann-Durchschein F, Bucsics T, Datz C, Dolak W, Ferlitsch A, Finkenstedt A, **Graziadei I**, Hametner S, Karnel F, Krones E, Maieron A, Mandorfer M, Peck-Radosavljevic M, Rainer F, Schwabl P, Stadlbauer V, Stauber R, Tilg H, Trauner M, Zoller H, Schöfl R, Fickert P. Austrian consensus guidelines on the management and treatment of portal hypertension (Billroth III). Wien Klin Wochenschr. 2017 Nov;129(Suppl 3):135-158

97. Kozbial K, Moser S, Al-Zoairy R, Schwarzer R, Datz C, Stauber R, Laferl H, Strasser M, Beinhardt S, Stättermayer AF, Gschwantler M, Zoller H, Maieron A, **Graziadei I**, Trauner M, Steindl-Munda P, Hofer H, Ferenci P. Follow-up of sustained virological responders with hepatitis C and advanced liver disease after interferon/ribavirin-free treatment. Liver Int. 2017 Nov 14. doi: 10.1111/liv.13629. [Epub ahead of print]

98. Strassburg CP, Beckebaum S, Geier A, Gotthardt D, Klein R, Melter M, Schott E, Spengler U, Tacke F, Trauner M, Weiler-Normann C, Weismüller TJ, Tannapfel A, Tischendorf JJ, Schramm C, Albert J, Allescher HD, Antoni C, Berg C, Bufler P, Dannel F, Dietrich C, Engelmann G, Feist E, Fickert P, Fischer L, Flechtenmacher C, Friedrich-Rust M, Giek A, Görtz RS, Herzer K, Hofer H, Hohenester S, Höhn M, Hüppe D, In der Smitten S, Jahnel J, Keitel-Anselmino V, Kirchner G, Kremer A, Lauenstein A, Lenzen H, Mayerle J, Müller T, Müllhaupt B, Nashan B, Rust C, Schattenberg JM, Schmidt H, Schreyer A, Sebode M, Siegmund B, Terjung B, Teufel A, van Thiel I, Wirth S, Witte T, Beuers U, Gerken G, **Graziadei I**, Lohse A, Manns MP, Tilg H. Practice guideline autoimmune liver diseases Z Gastroenterol. 2017 Nov;55(11):1135-1226.

99. Beinhardt S, Al-Zoairy R, Kozbial K, Stättermayer AF, Maieron A, Stauber R, Strasser M, Zoller H, **Graziadei I**, Rasoul-Rockenschaub S, Trauner M, Ferenci P, Hofer H. Long-term follow-up of ribavirin-free DAA-based treatment in HCV recurrence after orthotopic liver transplantation. Liver Int. 2018 Jul;38(7):1188-1197

100. Schaefer B, Viveiros A, Al-Zoairy R, Blach S, Brandon S, Razavi H, Dorn L, Finkenstedt A, Effenberger M, **Graziadei I**, Sarcletti M, Tilg H, Zoller H. Disease burden of hepatitis C in the Austrian state of Tyrol - Epidemiological data and model analysis to achieve elimination by 2030. PLoS One. 2018 Jul 12;13(7):e0200750. doi:
101. Kern B, Feurstein B, Fritz J, Fabritius C, Sucher R, **Graziadei I**, Bale R, Tilg H, Zoller H, Newsome P, Eschertzhuber S, Margreiter R, Öfner D, Schneeberger S. High incidence of hepatocellular carcinoma and postoperative complications in patients with nonalcoholic steatohepatitis as a primary indication for deceased liver transplantation. Eur J Gastroenterol Hepatol. 2018 Oct 12. doi:
102. Gschwantler M, Bamberger T, **Graziadei I**, Maieron A, Katalinic N, Stauber R. Burden of disease in patients with chronic hepatitis C in the Austrian REAL study. Wien Klin Wochenschr. 2018 Nov 14. doi: 10.1007/s00508-018-1404-2. [Epub ahead of print]

II. editorials

1. **IW Graziadei** and W. Vogel (2009) Treatment of chronic hepatitis C genotype 2 and 3 patients – more data, more questions? Hepatology 49(2):345-7
2. **IW Graziadei** and A. Cardenas (2015) Cardiovascular diseases after liver transplantation - a still emerging and unsolved problem! Liver Transpl. 21(7):870-2
3. A. Finkenstedt, **IW Graziadei (2016)**. Steatosis after liver transplantation: Is it really benign? Liver Transpl. May;22(5):585-7.

III. Review articles:

1. **IW Graziadei** and RH Wiesner (1997) Current diagnostic and management strategies in primary sclerosing cholangitis. IM - Internal Medicine 18, 41-57.
2. M. Trauner and **IW Graziadei** (1999) Mechanisms of action and therapeutic applications of ursodeoxycholic acid in chronic liver diseases. Aliment Pharmacol Ther 13, 979 – 995.
3. PJ Marotta, **IW Graziadei**, C. Ghent (2000) Cramps: A symptom of chronic liver diseases. Can J Gastroenterol, 14(Suppl. D), 21D – 25D.

4. **IW Graziadei** (2002). Recurrence of primary sclerosing cholangitis after liver transplantation. *Liver Transplantation* 8, 575-581.
5. **I. Graziadei** (2004) State of the art: Lebertransplantation. *J Gastroenterol Hepatol Erkr* 2: 47-52.
6. W. Jessner, **I. Graziadei**, W. Vogel (2005) Antivirale Therapie der chronischen Hepatitis C mit normalen Transaminasen. *J Gastroenterol Hepatol Erkr* 3: 15-18.
7. **I. Graziadei** (2006) Liver transplantation: organ allocation between Child and MELD. *WMW* 13: 410-415.
8. **I. Graziadei** (2006) Interferon bei dekompensierten Zirrhotikern. *J Gastroenterol Hepatol Erkr* 4: 10-13
9. **IW Graziadei** (2007) Living donor liver transplantation. *Trop Gastroenterol* 28; 45-50.
10. **I. Graziadei** (2008) Hepatitis B und C: Neue Substanzen in der Therapie. *J Gastroenterol Hepatol Erkr* 6: 25-31.
11. **IW Graziadei** (2011) Live donor liver transplantation for primary sclerosing cholangitis: is disease recurrence increased? *Curr Opin Gastroenterol*. 2011 27(3):301-5
12. **IW Graziadei** (2011) The clinical challenges of acute on chronic liver failure. *Liver Int.* 31 Suppl 3:24-6.
13. E. Krones, **I. Graziadei**, M. Trauner, P. Fickert (2012). Evolving concepts in primary sclerosing cholangitis. *Liver Int.* 32(3):352-69
14. **I. Graziadei** (2013) Overview: liver tumors. *Wien Med Wochenschr.* 163(5-6):109-12
15. **IW Graziadei** (2014) Recurrence of non-viral liver diseases after liver transplantation. *Clin Liver Dis.* 18(3):675-85.
16. **I. Graziadei** (2014) Intensive care treatment before and after liver transplantation *Med Klin Intensivmed Notfmed.* 109(6):411-7.
17. **I. Graziadei** (2014) Intensive care treatment before and after liver transplantation. *Med Klin Intensivmed Notfmed.* Sep;109(6):411-7
18. A. Finkenstedt, **I. Graziadei** (2018). State of the Art: Internistisches Lebertransplantations-management. *J Gastroenterol und Hepatol*; 16 (1): 21-28.

IV. case reports

1. T.Propst, A.Propst, K.Nachbaur, **I.Graziadei**, H.Willeit, R.Margreiter and W.Vogel (1997) Papillitis and vasculitis of the arteria spinalis anterior as complications of hepatitis C reinfection after liver transplantation. *Transpl Int* 10, 234-237.
2. CM Kähler, **I. Graziadei**, CJ Wiedermann, MP Kneussl and W. Vogel (2000) Successful use of continuous intravenous prostacyclin in a patient with severe portopulmonary hypertension. *Wien Klin Wochenschr* 112: 637-640.
3. C.Datz, **IW Graziadei**, O.Dietze, W.Jaschke, A.Königsrainer, F.Sandhofer, and R.Margreiter (2001) Massive progression of diffuse hepatic lymphangiomatosis after liver resection and rapid deterioration following liver transplantation. *Am J Gastroenterol* 96, 1278-81.
4. **IW Graziadei**, GE Obermoser, NT Sepp, KH Erhart and W. Vogel (2003). Drug-induced lupus like syndrome associated with severe autoimmune hepatitis. *Lupus* 12: 409-412.
5. RO Koch, **IW Graziadei**, R. Zangerle, N. Romani, H. Maier and W. Vogel (2003). Acute hepatic failure and lactate acidosis with antiretroviral treatment for HIV. *Wien Klin Wochenschr* 115: 135-140.
6. RO Koch, **I. Graziadei**, H. Zoller, H. Schwaighofer, W. Jaschke and W. Vogel (2003) Posttraumatic splenic artery aneurysm presenting as occult gastrointestinal bleeding. *Wien Klin Wochenschr* 115: 668- 671.
7. G. Millonig, **IW Graziadei**, P. Waldenberger, A. Königsrainer, W. Jaschke and W. Vogel (2004) Percutaneous management of a hepatic artery aneurysm-bleeding after liver transplantation. *CardioVasc Intervent Radiology*, 27: 525-528.
8. L. Hinterhuber, **IW Graziadei**, W. Jaschke and W. Vogel (2004) Bosentan treatment of portal hypertension. *Clin Gastro Hepatol*, 2:1039-42.
9. P. Jonetzko, **I. Graziadei**, K. Nachbaur, W. Vogel, S. Pankuweit, R. Zwick, O. Pachinger and G. Poelzl (2005). Fatal course of parvovirus B19-associated myocarditis in a female liver transplant recipient. *Liver Transplantation* 11: 463-466.

10. IE Kronberger, **IW Graziadei** and W. Vogel (2006). Small bowel adenocarcinoma in Crohn's disease: a case report and review of literature. World J Gastroenterol. 12:1317-20.
11. I.Hollmuller, S. Stadlmann, **I. Graziadei** and W. Vogel (2006) Clinico-histopathological characteristics of clopidogrel-induced hepatic injury: case report and review of literature. Eur J Gastroenterol Hepatol. 18: 931-34.
12. W. Jessner, M. Strasser, **I. Graziadei**, F. Berr and W. Vogel (2006) Sustained remission of chronic hepatitis C after acute hepatitis B superinfection. Scand J Infect Dis. 38: 818-21.

V. letters

1. R.Kaserbacher, T.Propst, A.Propst, **I.Graziadei**, G.Judmaier and W.Vogel (1993) Association between heterozygous 1-antitrypsin deficiency and genetic hemochromatosis. Hepatology 18, 707-708 (Letter).
2. R. Koch, H. Zoller, **I.Graziadei**, A. Propst and W. Vogel (2003) Cyclosporine-induced achalasia-like esophageal motility disorder in a liver transplant recipient: successful conversion to tacrolimus. Transplantation 76, 744-745 (Letter).
3. **IW Graziadei**, G. Millonig, W. Vogel (2003) Repeated graft loss caused by recurrent hepatic artery thrombosis. Liver Transplantation 9, 998-999 (Letter).
4. I. Stelzmueller, M. Biebl, **I. Graziadei**, S. Wiesmayr, R. Margreiter and H. Bonatti (2006). Regarding diarrhea in liver transplant recipients: etiology and management. Liver Transplantation 12: 163-4 (Letter).
5. S. Weiler, H. Zoller, **I. Graziadei**, W. Vogel, R. Bellmann-Weiler, M. Joannidis and R. Bellmann (2007) Altered pharmacokinetics of voriconazole in a patient with liver cirrhosis. Antimicrob Agents Chemother 51: 3459-60 (letter).
6. J. Auberger, **I. Graziadei**, J. Clausen, W. Vogel, D. Nachbaur (2012) Non-invasive transient elastography for the prediction of liver toxicity following hematopoietic SCT. Bone Marrow Transplant. Jun 18 (letter)

7. Q. Lai, AW Avolio, I. **Graziadei**, J. Lerut; European Hepatocellular Cancer Liver Transplant (EurHeCaLT) Study Group. (2014) Response to locoregional treatment and alpha-fetoprotein trend in liver transplant candidates for HCC: dwarfs standing on the shoulders of giants. *J Hepatol.* 60(6):1331-2 (letter).
8. Stern R, Hametner S, Ramona AZ, Moser S, Karpi A, Laferl H, Stauber RE, Zoller HM, Maieron A, Vogel W, **Graziadei I**, Gschwantler M, Kozbial K, Freissmuth C, Hofer H, Ferenci P. Interferon/Ribavirin-Free Antiviral Treatment in Septuagenarians and Octogenarians With Chronic Hepatitis C. *Am J Gastroenterol.* 2016 May;111(5):744-5.
9. Kozbial K, Moser S, Schwarzer R, Laferl H, Al-Zoairy R, Stauber R, Stättermayer AF, Beinhardt S, **Graziadei I**, Freissmuth C, Maieron A, Gschwantler M, Strasser M, Peck-Radosavljevic M, Trauner M, Hofer H, Ferenci P. Unexpected high incidence of hepatocellular carcinoma in cirrhotic patients with sustained virologic response following interferon-free direct-acting antiviral treatment. *J Hepatol.* 2016 Oct;65(4):856-858

VI. book chapters

1. H.Glossmann, G.Zernig, I.**Graziadei** and T.Moshammer (1989) Non L-type Ca²⁺ channel linked receptors for 1,4-dihydropyridines and phenylalkylamines, in: Nimodipine and central nervous system function (W.H.Grispen and J.Traber eds.) Schattauer Verlag 51 - 67.
2. I. **Graziadei**, M. Laimer, C. Ebenbichler, JR Patsch und W. Vogel (2000) Vergleichende Untersuchungen des Lipid- und Glukosestoffwechsels unter Tacrolimus und Ciclosporin, in Immunosuppression nach Lebertransplantation (P. Neuhaus, CE Broelsch, eds.) Pabst Verlag 165 – 171.
3. I.**Graziadei** (2006) Hepatitis B vor und nach Lebertransplantation, in Leitfaden der chronischen Infektionskrankheiten der Leber (M. Peck-Radosavljevic ed.), Thieme Verlag 53-57.
4. I.**Graziadei** (2006) Hepatitis C vor und nach Lebertransplantation, in Leitfaden der chronischen Infektionskrankheiten der Leber (M. Peck-Radosavljevic ed.), Thieme Verlag 92-97.

5. **I.Graziadei** (2009) Ernährung bei Leber- und Galleerkrankungen, in Klinische Ernährungsmedizin (M. Ledochowski ed.), Springer Verlag 207-218.